Next Article in Journal
A Typical Case Presentation with Spontaneous Visual Recovery in Patient Diagnosed with Leber Hereditary Optic Neuropathy Due to Rare Point Mutation in MT-ND4 Gene (m.11253T>C) and Literature Review
Previous Article in Journal
Our Evolving Understanding of ME/CFS
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 57
Issue 3
10.3390/medicina57030201
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

‘De Novo’ Brain AVMs—Hypotheses for Development and a Systematic Review of Reported Cases

by
Ioan Alexandru Florian
1,2,*,†,
Lehel Beni
1,†,
Vlad Moisoiu
1,†,
Teodora Larisa Timis
3,†,
Ioan Stefan Florian
1,2,
Adrian Balașa
4,5 and
Ioana Berindan-Neagoe
6
1
Clinic of Neurosurgery, Cluj County Emergency Clinical Hospital, 400012 Cluj-Napoca, Romania
2
Department of Neurosurgery, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
3
Department of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
4
Clinic of Neurosurgery, Tîrgu Mureș County Clinical Emergency Hospital, 540136 Tîrgu Mureș, Romania
5
Department of Neurosurgery, Tîrgu Mureș University of Medicine, Pharmacy, Science and Technology, 540139 Tîrgu Mureș, Romania
6
Research Center for Functional Genomics, Biomedicine, and Translational Medicine, Institute of Doctoral Studies, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
*
Author to whom correspondence should be addressed.
†
Equal contributions as first author.
Medicina 2021, 57(3), 201; https://doi.org/10.3390/medicina57030201
Submission received: 16 January 2021 / Revised: 15 February 2021 / Accepted: 22 February 2021 / Published: 26 February 2021
(This article belongs to the Section Neurology)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background and Objectives: Brain arteriovenous malformations AVMs have been consistently regarded as congenital malformations of the cerebral vasculature. However, recent case reports describing “de novo AVMs” have sparked a growing debate on the nature of these lesions. Materials and Methods: We have performed a systematic review of the literature concerning de novo AVMs utilizing the PubMed and Google Academic databases. Termes used in the search were “AVM,” “arteriovenous,” “de novo,” and “acquired,” in all possible combinations. Results: 53 articles including a total of 58 patients harboring allegedly acquired AVMs were identified by researching the literature. Of these, 32 were male (55.17%), and 25 were female (43.10%). Mean age at de novo AVM diagnosis was 27.833 years (standard deviation (SD) of 21.215 years and a 95% confidence interval (CI) of 22.3 to 33.3). Most de novo AVMs were managed via microsurgical resection (20 out of 58, 34.48%), followed by radiosurgery and conservative treatment for 11 patients (18.97%) each, endovascular embolization combined with resection for five patients (8.62%), and embolization alone for three (5.17%), the remaining eight cases (13.79%) having an unspecified therapy. Conclusions: Increasing evidence suggests that some of the AVMs discovered develop some time after birth. We are still a long way from finally elucidating their true nature, though there is reason to believe that they can also appear after birth. Thus, we reason that the de novo AVMs are the result of a ‘second hit’ of a variable type, such as a previous intracranial hemorrhage or vascular pathology. The congenital or acquired characteristic of AVMs may have a tremendous impact on prognosis, risk of hemorrhage, and short and long-term management.

1. Introduction

Arteriovenous malformations (AVMs) of the brain consist of feeder arteries that amalgamate and form a nidus, shunting the oxygenated blood directly into the venous system without an interposing capillary network [1,2,3,4]. The most common and undeniably the most severe clinical presentation is intracranial hemorrhage, AVMs representing an important source of mortality and morbidity especially in the younger population. Epilepsy, progressive neurological deficit, and chronic headache are less frequently encountered in patients harboring this pathology. Asymptomatic patients may benefit from simple clinical and imagistic observation, whereas those with minimal symptoms can be managed conservatively. Currently the most effective and permanent treatment method or ruptured or symptomatic AVMs consists of microsurgical resection of the nidus and rigorous hemostasis, but radiosurgery and endovascular embolization are also viable management options.
AVMs are traditionally considered congenital, an estimated 95% of these lesions being sporadic in nature, whereas the remaining 5% are familial and most often associated with hereditary hemorrhagic telangiectasia (HHT) [4]. The congenital aspect derives from the observation that these lesions may occur at any age, from infants and children to adults and elderly alike, even though there is a scarcity of conclusive data to demonstrate this fact [5,6,7].
Our current grasp of cerebral AVMs has dramatically improved over the last few decades, by delving into the genetic and epigenetic intricacies of their pathogenesis [8,9,10]. Data concerning the molecular underlying of AVMs come from AVM syndromes as well as from the analysis of sporadic cases of AVMs. For instance, genetic events involving members of the transforming growth factor-β (TGF-β) signaling, namely Endoglin (ENG) and Activin A receptor type I (ACVR1 or ALK1) are causative in HHT type 1 and type 2, respectively [11,12]. Mutations in SMAD4, which is a downstream effector of TGF-β, causes combined syndrome of HHT with juvenile polyposis [13]. In agreement with such an interpretation, conditional knock out of either ENG or ALK1 resulted in arteriovenous malformations of the skin in mice only after a secondary injury, for example wounding [14,15]. Moreover, vascular endothelial growth factor (VEGF) has the ability to mimic this wounding effect on skin AVM development, at least in animal models [16]. In the case of the more common sporadically occurring AVMs, somatic KRAS mutations were discovered in approximately 55% of brain AVM specimens, also linked to a lower patient age, and a larger nidus mean size [17,18,19], whereas the non-coding polymorphism in ALK1 (ALK1 IVS3-35A>G) was established as a genetic risk factor in two independent studies [20,21]. Other polymorphisms linked to sporadic AVMs include polymorphisms in ENG [20], interleukin-1β (IL1B) [22] and VEGF [23]. Even so, we are currently unable to effectively validate whether these malformations actually develop during embryogenesis and evolve during one’s lifetime, or if they appear at a later point in time when certain microenvironmental conditions are met.
There is a mounting number of pertinent case reports detailing AVMs that occurred sporadically after credible evidence of their initial absence. Either adequate imaging studies or intraoperative examinations preceded the certain appearance of these vascular malformations, which were then discovered at a variable interval. A diversity of preexisting circumstances or pathologies either influenced or initiated the development of AVMs in already susceptible patients. Ischemic stroke and transient ischemic attacks (TIA) were among the most common ailments preceding de novo AVMs [24], as were seizures [25]. Certain individuals previously harbored another type of intracranial vascular pathology, or even a differently located AVM, highlighting the irrefutable predisposition for such an occurrence [26]. Intracranial tumors with a highly vascular component have also been described as potential triggers for previously absent AVMs [27]. An earlier hemorrhagic episode [28] and even head trauma of variable severity have also been reported as generators for de novo AVMs [29].
Notwithstanding the fact that cerebral AVMs are a rare pathology, they are cited as the most common cause of intracranial hemorrhage in children and young adults, leading to a lifelong threat of death or disability [2,3,4,30,31]. As such, elucidating their true natural history is crucial in order to establish the best possible course of diagnosis and management, and help lessen their socio-economic encumberment. In this systematic review we have included, to the best of our knowledge, all such incidences reported in the available and relevant literature.

2. Material and Methods

We performed a rigorous examination of the PubMed and Google Academic medical databases utilizing the terms “AVM”, “arteriovenous malformation”, “brain”, “cerebral”, “intracranial”, “acquired”, and “de novo”, and all of their possible combinations. Our search only identified articles in English, and we excluded animal studies from the systematic review. Other systematic reviews were also discarded. Afterwards, we methodically assessed the references of the manuscripts gathered for any additional articles significant to our research. Among acquired AVMs that appeared after a previous pathology or injury, we have also included AVMs that recurred at a different site after a previous angiographically-demonstrated occlusion. We paid special attention not to include data from overlapping series that were published at a different time or in another journal. Nevertheless, certain redundancies cannot be completely dismissed.
Microsoft® Excel for Mac, version 16.37, was used to create a spreadsheet wherein all relevant cases were gathered in order to create our database. The same program was utilized to perform descriptive statistics, as well as to create the appropriate graphs.

3. Results

3.1. Literature Data

As of June 2020, our search yielded 218 results on PubMed. After careful consideration of titles and abstracts, we have eliminated 163 articles which were not relevant to the subject at hand, followed by the exclusion of an additional 16 that were either in vitro or animal studies, other systematic reviews, case reports detailing other vascular pathologies such as arteriovenous fistulas, aneurysms, cavernomas, or AVMs outside of the cranial cavity. Among these, two articles which represented correspondence regarding the same article, as well as a letter to the editor concerning another article, were eliminated. Moreover, 19 further articles were identified subsequent to the scrupulous reference review of the previously retrieved studies. As such, we have obtained a total of 58 cases of presumed de novo AVMs from 53 articles matching our inclusion criteria. We then divided the patients according to pathological subgroup of the presumed predisposing disease, and in alphabetical order of the first author, as seen in Table 1. The flow-chart for our literature gathering is summarized in Figure 1.

3.2. Demographic Data and Descriptive Statistics

We identified 58 patients harboring de novo AVMs (AVMs that appeared on subsequent imaging studies after a definitive negative one), out of which 32 were male (55.17%), and 25 were female (43.10%). Mean age at de novo AVM diagnosis was 27.833 years (standard deviation (SD) of 21.215 years and a 95% confidence interval (CI) of 22.3 to 33.3), with the extremes being 2.5 years [32] and 80 years [26], respectively (Figure 2). The gender and age of one patient (1.72%) was unspecified in the respective case report [33] and was therefore not included when calculating mean age and standard deviation.
Whereas original investigations varied between CT (either contrast-enhanced or otherwise), MRI (including magnetic resonance venography), tran-sfontanellar ultrasonography (US) in one case, or DSA, or any combination of these, all purportedly de novo AVMs were subsequently confirmed via angiography, with the exception of two (3.44%) that only had MRI scans [34,35] or CT scans [1,36]. The time from initial imaging study, which did not reveal any AVMs, and the diagnostic study varied from three months [37] to 25 years [36], the average being 7.67 years and with a SD of 6.008 years (95% CI of 6.11 to 9.23).
We grouped the patients according to the major underlying pathology allegedly associated with the development of de novo AVMs. We considered ten major categories, in descending order of frequency: preexisting cerebrovascular malformations (including other AVMs, cavernomas and aneurysms)—13 patients (22.41%); hemorrhagic stroke—11 cases (20.69%); epileptic seizures—nine individuals (15.52%); brain tumors—six patients (10.34%); ischemic stroke—five patients (8.62%); Moyamoya disease—four cases (6.9%); traumatic brain injury—three patients (5.17%); and genetic syndromes, inflammatory diseases, and liver cirrhosis, each with two individuals (3.45%). This is also illustrated in Figure 3.
Once diagnosed, the majority of de novo AVMs were treated via microsurgical resection (20 out of 58, or 34.48%), followed by radiosurgery and conservative management for 11 patients (18.97%) each (Figure 4). Endovascular embolization combined with subsequent resection was the choice method of therapy for five patients (8.62%), whereas only three (5.17%) underwent embolization alone. For the other eight cases (13.79%), therapy was not mentioned within their respective articles.
Half of the patients had a favorable outcome after treatment, either being neurologically intact, or recovering partially or completely. The natural history of five (8.62%) culminated with death, the shortest period being only six days after surgery due to massive pulmonary embolism [38], and the longest at 3.5 years after diagnosis and endovascular embolization of the AVM [32]. The outcome was not specified for the remaining 24 cases (41.38%).

4. Discussion

4.1. Data Review

As evidenced by the demographic data, the majority of patients reported with de novo AVMs (64.91%) were under the age of 30 at the time of diagnosis, highlighting that even under the circumstances of acquired vascular malformations, this remains a pathology of the young. Male-to-female ratio was 1.28, with a slight yet statistically insignificant predominance in the male gender, which corresponds to the patient populations described in the majority of reported series [2,3,4,30,31]. The interval between the initial investigation and definitive identification of acquired AVMs varied widely, the shortest being only three months in a patient who harbored an anaplastic astrocytoma immediately adjacent to the AVM itself [37], and the lengthiest reaching 25 years in a patient who had been treated with phenytoin for epileptic seizures during this time [36]. However, we point out that in the report of Ozsarac et al., the initial angiographic studies were not available, and it was the patient himself who stated upon recollection that those investigations had been normal. As such, it is difficult to properly ascertain the moment when the AVM appeared.
It may be worthwhile mentioning that some critics believe de novo AVMs are in fact occult vascular lesions, only later visible as the result of low sensitivity and specificity of certain imaging techniques, specifically DSA [29,39]. Even so, the majority of case reports illustrating de novo AVMs have been published within the last two decades, during an ever-increasing accessibility to high-resolution and, serial cross-sectional imaging techniques, as well as an upsurge in detection of once-occult intracranial lesions.
In the following section, we will discuss the cases according to the underlying pathologies and emit a hypothesis on their probably pathogenesis. Due to the rare nature of acquired AVMs and, hence of their pathogenesis, the current theories regarding congenital AVM development may not apply here.

4.2. Finding the Culprit—Hypothesized Causes for De Novo AVMs

4.2.1. Intracranial Vascular Malformations and Aneurysms

The majority of the reported patients included in this systematic review had a previous cerebral vascular malformation or degenerative lesion before the occurrence of a de novo AVM (13, or 22.41%). These ranged from dural arteriovenous fistulas (dAVFs), preexisting AVMs or cavernous malformations, or even aneurysms. Patients with Moyamoya disease are covered in a separate section, due to its frequency and implications. Among these patients, seven (12.07%) had a previous AVM that was treated either invasively or conservatively, the acquired lesion appearing either in the same location, or separately [12,26,40,41,42]. Nagm et al. suspected that the occurrence of de novo AVMs was the result of certain environmental stimuli that triggered angiogenesis via the upregulation of TGF-β and VEGF [43]. They also entertained the concept of increased immunoactivity processes, since the analysis of the malformation samples acquired from the second intervention in their patient revealed heightened levels of ENG in the perivascular area, as well as accentuated immunoreactivity for phosphorylated extracellular signal-regulated kinase (pERK).
In three of the patients, it was hypothesized that entrance radiation originating from stereotactic radiosurgery (SRS)-treated vascular lesions either facilitated or triggered the development of de novo AVMs [26,41,43]. After the removal of the recurrent nidus, Kawashima et al. discovered a slightly increased Ki-67 expression, in conjunction with negative expression of both ENG and VEGF, whereas raised ENG expression was noticed in the area surrounding the nidus and exhibiting radiation-induced inflammation [41]. Another prospect is that, in the scenario of a recurring AVM, the recanalization of thrombosed vessels can ensue at some point in time after radiosurgery [43]. Correspondingly, the blood flow redistribution ensuing gradual obliteration of vascular malformations may expedite immature vessels around the original lesion, generating a secondary AVM. Therapeutic exposure to radiation in various pathologies has been demonstrated to generate endothelial cell injury, thus prompting vascular remodeling and VEGF and TGF-β production [24,26,44,45,46,47,48]. In addition, radiation itself may produce mutations in the genes involved in AVM development. It is therefore likely that radiation indeed plays as a veritable ‘second hit’ in the generation of de novo AVMs.
Prior to the discovery of acquired AVMs, three of the cases presented suffered from cavernomas, all of which were situated in different parts of the brain than the secondary malformation [27,49,50]. While cavernomas and AVMs possess distinct genetic backgrounds in their pathogenesis [51,52], these cases may suggest that there might be a common origin within the signaling pathway of these vascular malformations, supplementing the already enthralling complexity of intracranial AVMs [50]. Perhaps a less alluring but nonetheless credible theory is that behind these de novo lesions lies an angiogenically dynamic microenvironment stemming from a mixture of insults brought on by surgical trauma and cerebral hemorrhage [28].
Disturbances within the cerebral venous drainage may also play a part in the genesis of de novo AVMs, as it does for dAVFs [42]. A child and an adult, both male, harbored dAVFs and were treated via embolization and radiosurgery combined with embolization, respectively [53,54]. While it could be reasoned that both AVMs were simply missed on the initial scans, an intriguing possibility is that the local venous hypertension brought about by the occlusion of the dAVFs led to the growth of de novo AVMs.
A single case of surgically clipped unruptured intracranial aneurysm, without any other concomitant vascular malformations, was linked to an acquired AVM in the territory of that respective artery [55]. The authors argued that certain physiological stimuli such as vascular shear stress and prolonged cerebral hypoxia after aneurysmal clipping might reactivate angiogenesis. As this is an isolated incidence, other possibilities have yet to be expounded.

4.2.2. Hemorrhagic Stroke

According to the information presented, hemorrhagic stroke from various sources is the single most common primary brain injury leading to the formation of de novo AVMs within the same site. Although angiographically occult fistulas masked by hematomas, thrombosis, arterial feeder vasospasm, or posthemorrhagic brain edema cannot be dismissed, a possible pathophysiological mechanism for AVM generation in a hemorrhagic cerebral environment should be postulated. It is likely that hemorrhagic stroke in conjunction with surgical trauma fosters appropriate angiogenetic conditions [28,56,57]. It may also seem likely that at least some of these AVMs stemmed from a small and previously missed angioma [58]. After surgical resection, the available empty space and probable repeated silent bleeds resulting in a progressive vascular enlargement in the hematoma cavity may also explain these occurrences [59]. Jeffree et al. conjectured that AVMs might develop not though the means of dilatation of preexisting vessels, but via the generation of brand-new vessels [60]. They proposed that the levels of certain growth factors increase upon endothelial cell exposure to shear stress, later resulting in the development of a vascular network and recruitment of new vessels within a previously occult and asymptomatic malformation. The authors also speculated an alternative, namely that the hematoma itself triggers de novo AVM formation concurrently with its own resolution.
Nevertheless, it appears that acquired AVMs may develop even remotely from the location of the initial hemorrhage. One of the patients in the series by Jeffree et al. suffered from a left parietal hematoma, followed by a right parieto-occipital de novo AVM found ten years afterward [60]. The case described by Miyasaka et al. had a right parietal hematoma eight years before three AVMs were revealed [56]. Only one grew near the hematic cavity, whereas one was situated in the frontal lobe of the same hemisphere, and the remaining one in the left occipital lobe. Four more individuals who experienced SAH of unknown origin developed de novo AVMs in various areas of the brain, any time between 2 and 23 years after the original injury [33,57,58,61]. Nakamura et al. reported a more unique instance, wherein a left frontal intraparenchymal hemorrhage was surgically evacuated, followed by the therapeutic local implantation of mesenchymal stem cells secreting the neuroprotective glucagon-like peptide-1 (GLP-1) [62]. Despite some criticism [62], the authors clearly infirmed the presence of any vascular malformations at the site of surgery [62,63]. At the three-year mark after the intervention, a ruptured AVM was diagnosed in the same region of the brain. They hypothesized that aside from VEGF, GLP-1 might also play a role in promoting angiogenesis and vessel proliferation. Validating the angiogenetic role of intracranial hematomas may be possible in the near future.

4.2.3. Seizures

Several instances of epileptic convulsions with no discernible underlying causes have been associated with acquired AVMs after a variable period of time since the onset of the seizures [25,35,64,65,66,67,68]. According to numerous authors, as well as our own experience, seizures represent the second most common form of manifestation of cerebral AVMs [1,31,69]. It has been previously demonstrated that VEGF is upregulated within neural and glial cells following epileptic seizures, most likely acting as a mechanism to combat postictal neurodegeneration [25,35,67,70,71,72,73,74]. Moreover, preclinical studies have revealed a variety of beneficial effects of VEGF elevation in epilepsy and status epilepticus [75,76,77]. On the other hand, pathological upsurge of VEGF can result in a disrupted blood-brain-barrier integrity, and may also further the progression of certain diseases such as demyelinating injuries and vascular malformations [71,73,75].
One particular case was preceded by a single episode of seizures nine years prior to the discovery of an AVM, which was absent on the initial MRI scan [35]. Similarly, a seven-year-old boy diagnosed with a de novo AVM experienced febrile seizures four years prior to definitive imaging study [68]. These two cases may suggest that even a solitary episode of epileptic convulsions creates the appropriate angiogenetic conditions for AVM growth. Withal, subcortical band heterotopia (SBH), a neural migration disorder, is also associated with pharmacoresistant epilepsy [78,79,80]. A nine-year-old girl with SBH also developed an acquired AVM after three years of seizures and developmental delay [67]. Furthermore, it seems that there is no requirement for the seizures to have a tonic-clonic characteristic, as exemplified in a case by Kilbourn et al. [64]. This patient was diagnosed with hydrocephalus at an infant age, and later developed autism and absence seizures, a de novo AVM being discovered at the age of 18 years. As such, it is possible that epilepsy, in any of its forms, may play a decisive role in the appearance of acquired AVMs through an exaggerated and detrimental protective mechanism against neurodegeneration.

4.2.4. Brain Tumors

Although rare instances, intracranial neoplasms with a high vascularity coexisting with AVMs have been described in the recent past [81,82,83,84]. AVMs occurring after the treatment of a previous brain tumor are also remarkably rare [27,37,44,85,86]. In the case reported by Bennet et al. of a de novo cerebellar AVM occurring after the surgical resection of a vermis hemangioblastoma, it is likely that the altered hemodynamic conditions, which stemmed from the removal of the tumor, played a crucial role in the evolution of the vascular lesion [85]. It may also seem plausible that the AVM coexisted with the hemangioblastoma but was occult beforehand. Medvedev et al. described a case in which a cerebellar AVM and a hemangioblastoma coincided, also theorizing a common ancestry linking these two pathologies [87]. A similar mechanism might also be involved in the appearance of an acquired brain AVM after recurrent meningioma surgery [27]. Likewise, malignant glial tumors foster a highly proangiogenic environment, as quantified by the enhanced production of VEGF, which could prove a crucial stimulus for a de novo AVM occurrence [37,38]. A second possible reason is that an environmental exposure gave rise to both the neoplasm and the malformation, although the incriminated factor is uncertain [38,70]. Radiosurgery has been incriminated as a probable etiologic factor for malignant brain tumors, even after therapy for AVMs, despite the risks being relatively low [88,89,90]. The exposure to radiation could also be considered a stimulus for these malformations, since tumors of the fourth ventricle (an ependymoma and a medulloblastoma, respectively) undergoing postoperative radiotherapy later developed de novo AVMs [44,86]. This might be supported by the vasculopathy and vessel remodeling following radiation therapy. Regardless of etiological considerations, the simple association with such neoplasms warrants a poor prognosis and a low short-term survival from the start [27,37,38,44,81,82,83,84,85,86,87].

4.2.5. Ischemic Stroke, Venous Sinus Thrombosis, and Transient Ischemic Attacks (TIA)

Only very few cases of de novo AVMs have been correlated with ischemic events of the brain. Pabaney et al. argued that an inflammatory or ischemic lesion could have hastened the development of acquired AVMs in contrast with congenital AVMs [24]. They reasoned that the stroke acted as a ‘second-hit’ that resulted in the formation a de novo AVM. Previously, it has been demonstrated that ischemia has the potential to trigger vascular proliferation via an amplified expression of hypoxia-inducible factor-1 (HIF-1), resulting in an uninhibited vascular proliferation and the occurrence of arteriovenous shunts within a patient with genetic susceptibility and alterations regarding angiogenesis and inflammatory cascades [24,51,91]. The appearance of de novo vascular lesions could also be a response to injury mechanism after stroke [92]. This might actually be the case, as other vascular malformations (i.e., dural and pial arteriovenous fistulas) can originate from infection, inflammation, or traumatic injury, advocating the concept of environmental factors promoting angiogenesis [52,66]. Regarding venous sinus thrombosis, it may seem plausible that the increased venous pressure and subsequent hypoxia in the adjacent tissues arising from such an event leads to an enhanced angiogenic activity [14,45,66,93]. During embryological growth, venous hypertension could be the result of occlusion, stenosis or agenesis. Otherwise, cerebral ischemia itself may offer a physiological incentive for angiographically occult AVMs to enlarge and become patent [94]. It is worthwhile mentioning that among this group of de novo AVM patients, only one had an ischemic event during infancy [92], the other individuals being adults at the time of initial injury.

4.2.6. Moyamoya Disease (MMD)

MMD is defined as a rare chronic occlusive pathology of the cerebral vasculature, having an unidentified etiology [95,96,97,98]. It is characterized by a series of bilateral steno-occlusive alterations in the terminal portion of the internal carotid artery (ICA) and its branches, as well as a coexisting abnormal network of collateral vessels at the base of the brain. Its presentation differs according to age, children most often manifesting epileptic seizures and ischemic events, while in adults it generally leads to hemorrhagic stroke. There have been a few instances in which AVMs preceded the development of MMD, hatching the hypothesis that the increased amount of blood traveling within the malformation itself creates a turbulent flow level of the common carotid artery bifurcation, in turn generating the hyperplasia of the intima and the ensuing collateralization and progression of an acquired form of MMD [99,100,101]. The association between MMD and ulterior de novo AVMs has been described in a small number of case reports, all of which were pediatric, potentially turning the aforementioned hypothesis on its head [95,96,97,98,99,100,101]. It is possible that the analogous biological backgrounds of these two pathologies regarding the enhanced expression of proangiogenic molecules such as VEGF, or certain inflammatory molecules including tumor necrosis factor α (TNFα), MMP and IL-6, led to the occurrence of AVMs after the progression of MMD [95]. This might be the case, as the patient described by Fujimura et al. harbored an AVM supplied by the posterior circulation, which by definition was not affected by MMD. Additionally, this patient concomitantly suffered from sickle cell disease, yet no explanation could be offered whether this condition had any influence on either the appearance of MMD or the AVM. Another plausible explanation is that MMD in these patients produced an angiogenic failure, which in turn resulted in the formation of anomalous arteriovenous shunts [96]. As Schmit et al. pointed out, it could also be stipulated that the hyperangiogenic microenvironment predominant in MMD, in conjunction with a local proangiogenic stimulus (for instance VEGF or fibroblastic growth factor—FGF) as a consequence of cerebral infarction, would have been sufficient for an AVM to develop on that precise spot [98]. The role of genetic factors, whether congenital or acquired, in the presence of prolonged hypoperfusion should also be considered [97]. Nevertheless, the probability that the AVMs coexisted with MMD but were angiographically occult at the time of initial angiography cannot be entirely ruled out.
As observed in these collection of case reports, brain infarction, and associated cerebrovascular pathologies associated, may generate sufficient stimuli for an AVM to develop postnatally, at least if the patient possesses a certain susceptibility. More research is needed in this field to precisely determine the nature of these predispositions.

4.2.7. Traumatic Brain Injury (TBI)

Whether head trauma itself actually contributes to the formation of a proangiogenic environment, or its association to de novo AVMs is purely coincidental, remains to be proven. Traumatic injury has, however, been reported as an etiologic factor for arteriovenous fistulae [102,103,104]. The case described by Gonzalez et al., of a three-year-old girl who suffered a mild TBI as a result of traffic accident, developed a delayed hemorrhagic lesion that manifested through generalized epileptic seizures [29]. These seizures became increasingly difficult to control, lasting for four years before the diagnosis of a de novo AVM was established. As anteriorly discussed, both the hemorrhagic and the epileptic components could be held accountable for the appearance of an acquired AVM, although the hematoma had a left frontal placement, whereas the vascular lesion was situated in the right posterior temporal lobe. No hemorrhagic collections were identified in the vicinity of the AVM to mask this anomaly. A comparable case, in which an 11-month-old girl experienced a severe TBI with an acute subdural hematoma on the left convexity, was diagnosed with an ipsilateral de novo AVM almost 11 years later, after suffering from seizure disorder for around six years [105]. In this instance, the patient was also diagnosed with posttraumatic encephalomalacia, which could in theory act as a suitable terrain for an abnormal vasculature in a developing brain. Similarly, a young boy suffered a blunt head injury and subsequent subarachnoid hemorrhage from an unknown source, and developed an AVM in the right frontal lobe nine years after the initial incident [106]. We hypothesize that the presence of TBI resulting in intracranial hemorrhage or seizure disorder may act as a ‘second hit’ that generates a de novo AVM in patients with genetic susceptibility via VEGF upregulation (Figure 5). This theory needs to be further studied.

4.2.8. Genetic Syndromes

HHT is a systemic autosomal dominant genetic syndrome with a marked predisposition to develop intracranial AVMs [6,7,11,12,46,51]. Two genes that have been linked to the development of HHT are the ENG gene, which is correlated with HHT1 as well as a higher prevalence of AVMs, and the ACVRL1 or ALK1 gene, which is associated with the HHT2 phenotype and a lower brain AVM incidence [11,12]. A single patient in the reported literature was confirmed to have HHT and developed a de novo AVM [46]. At five months of age, he underwent screening for HHT, as both his mother and older brother suffered from this syndrome and harbored a symptomatic AVM of the brain and of the spine respectively, despite being asymptomatic himself. At the age of five years, a de novo AVM became manifest and the patient underwent preoperative embolization and microsurgical resection. This case underlines the potential of these vascular malformations to appear and expand within highly vulnerable individuals, without necessarily requiring the involvement of external factors. AVMs in HHT have been shown to have a bidirectional evolution, possessing both the possibility of expansion and to regression [34]. Komiyama entertained the hypothesis that congenital brain AVMs could develop until the age of two years [93]. We, however, believe that there is no predefined interval within which these lesions materialize.
Additionally, a newborn diagnosed with hepatic hemangiomatosis and congestive heart failure suffered from a de novo AVM in the left cerebellopontine angle (CPA), which was treated via endovascular embolization at three and four years of age respectively [32]. Before the vascular malformation was found, MRI revealed two enhancing lesions in the left CPA and pineal region, which could have been brain hemangiomas. It was not mentioned whether or not she was tested for HHT or any other genetic syndrome, and she died because of brain hemorrhage at six-years-old. Brain AVMs and hemangioblastomas have been described in patients with diffuse neonatal hemangioma-tosis (DNH) in the past [107,108]. The authors of the respective case report proposed two possibilities: either the enlargement and progression of a coincidental AVM adjacent to the preexisting CPA hemangioma, or the conversion of said hemangioma into an AVM [32]. As there are only a finite number of individuals with diffuse neonatal hemangioma-tosis, it might prove challenging to screen them for acquired cerebral AVMs.

4.2.9. Inflammatory Diseases

Only two cases of inflammatory diseases not related to the cerebral vasculature and de novo AVMs were described in the literature. The first was of an unidentified inflammation or demyelinating lesion in the brainstem [109], and the second was associated with a previously diagnosed Bell’s palsy on the same side [39]. A probable mechanism is the overexpression of VEGF as a result of the inflammatory process, similar to the mechanism explained in ischemic stroke [39,52,66]. Another explanation could be increasing hemodynamic stress due to the inflammation, leading to vascular remodeling.

4.2.10. Liver Cirrhosis

Cirrhosis defines a diffuse fibrosis of the liver and the alteration of the hepatic microarchitecture into structurally anomalous nodules. Despite that, to the extent of our knowledge, only two instances of de novo brain AVMs were described in patients suffering from cirrhosis, and that the correlation between these two pathologies was poorly studied, we nevertheless consider it worthwhile mentioning [6,110]. Peripheral systemic vascular malformations are already considered a mark of advanced chronic liver disease; hence it is tantalizing to assume that these lesions and cerebral AVMs share a common set of mechanisms and etiologic factors. Among these we point out an excessive production alongside a clearance reduction of factors such as VEGF, TNF- α, IL-6, MMP-3 and MMP-9, or nitric oxide synthetase (NOS), as well as a decreased catabolism of estrogens [5,110]. To further support this assumption, Shimoda et al. illustrated the case of spontaneous AVM disappearance two years after a successful liver transplantation in a patient with alcohol-induced cirrhosis [111]. It is therefore likely that the alterations instigated by the state of venous hypertension and thrombosis, combined with a hepatic “second hit,” provides the necessary stimuli for an intracranial AVM to develop in cirrhosis. More such patients should be investigated for cerebral vascular malformations further along the course of their chronic liver disease before finally establishing this correlation.

4.3. Past, Present, Future, and Personal Opinions

Up until recently, AVMs were adamantly considered congenital disorders with the capacity to evolve, rupture, regress, and even recur after treatment [52]. Contemporary evidence, including the case reports incorporated in this study, suggests that we are still a long way from fully elucidating these lesions, which could actually also be acquired. In research on adult mice, Chen et al. demonstrated that the deletion of ACVRL1 within endothelial cells resulted in elevated local endothelial cell proliferation throughout brain angiogenesis, as well as the induction of de novo AVMs [112]. Similarly, Walker et al. obtained lesions resembling human AVMs in adult mice after co-injecting adenoviral vector exhibiting Cre recombinase and adeno-associated viral vectors containing VEGF within their basal ganglia, thereby producing ACVRL1 mutation [113]. In their study, Park et al. demonstrated that either physiological or environmental stimuli such as injuries, alongside the respective genetic deletion, are needed for ACVRL1-deficient blood vessels to evolve into AVMs within adult mice [15]. Zhu et al. also managed to trigger the formation of AVMs in adult mice, this time via CRISPR/Cas9-mediated ACVRL1 gene mutations [114]. Although other experimental models exist, it is beyond the scope of this review to present them exhaustively. It is, however, safe to assume that a number of genetic mutations, in conjunction with the appropriate environmental factors, may lead to the development of de novo AVMs.
Evidence from several of the reported case studies and series suggest that radiotherapy-related injury triggers an increased VEGF production as a response-to-injury type of adaptation, which can result in the spontaneous formation of brain vascular malformations [26,41,52,115,116,117]. While the majority of these lesions are cavernomas, it cannot be fully disproved that radiation can also induce the formation of AVMs. We believe that the adaptive changes in the cerebral vasculature occurring after stereotactic radiosurgery can also induce the exaggerated angiogenesis necessary for de novo AVMs.
Individuals in which intraparenchymal hemorrhage (IPH) were surgically removed serve as irrefutable evidence that de novo AVMs can develop in the hematic cavity, without preexisting vascular lesions in the respective regions [56,59,60,118]. We tend to consider these cases especially because the intraoperative aspect cannot be replicated entirely by imaging studies, at least with current technology.
Seizures present a dual quality, on the one hand being the second most common symptom for brain AVMs, and on the other as a possible generator for de novo AVMs [25,35,36,64,66,67,68]. Although we cannot contradict the fact that epilepsy can cause the expansion of these lesions, the possibility that a preexisting angiographically occult cerebral vascular malformation triggered the aforementioned seizures cannot be completely negated.
However, arguably the most important aspect is that all of the reported cases of de novo AVMs had an initial symptom or a preexistent underlying pathology. It is therefore tempting to believe that the actual number of such individuals is much higher, yet for various reasons, many of these patients are not investigated prior to the occurrence of AVMs. The fact that not all patients had an initial DSA might be a confounding factor, as the diagnosis of brain AVM might have been missed in this case. As the majority of these patients suffered from vascular conditions such as MMD, hemorrhagic stroke, aneurysms or other allegedly congenital vascular anomalies, the predisposition for developing AVMs was indubitably present, requiring a ‘second hit’ stimulus for AVMs to properly appear (Figure 5) [66].
One of the major limitations regarding the alteration of the ‘congenital AVM doctrine’ arises from the limited number of de novo lesions, which are mostly found in singular case reports. Additionally, the exact pathophysiological mechanisms of AVM growth are conjectured, although not fully understood. A recent consensus meeting of international neurosurgical experts debated whether AVMs should be regarded as congenital or acquired [7]. The authors all agreed that the genetic predisposition is insufficient to induce AVM formation by itself, and that a ‘second hit’ of variable nature is always required. Despite the fact that the majority of patients with brain AVMs harbor mutations of the KRAS gene [17,18], certain somatic mutations have very low frequencies within these lesions. This in itself raises the concern whether these mutations actually possess functionality in AVMs development, or whether they can be accurately quantified. Another limitation that the authors acknowledge is the hypothetical nature of this review. This stems from the fact that de novo AVMs are extremely scarce, and the data surrounding their development is reduced. However, we hope that the mechanisms proposed in this work will be more adequately studied in the near future.
Therefore, we propose that brain AVMs can be either present at birth and able to evolve or regress, or acquired but in the presence of preexisting genetic susceptibility. There needs to be an association between clinical, genetic, and animal studies in order to verify this hypothesis.

5. Conclusions

Increasing evidence suggests that at least some of the AVMs discovered develop some time after birth. We are still a long way from finally elucidating their true nature, though there is reason to believe that they can also appear after a proposed ‘second hit’ during a patient’s lifetime (Figure 5). The congenital or acquired characteristic of AVMs may have a tremendous impact on prognosis, risk of hemorrhage, and short and long-term management.
This systematic review presents the reported cases of de novo brain AVMs in the current literature. Despite being a rare pathology, AVMs represent the most frequent cause of intracranial hemorrhage in young patients. Furthermore, it is possible that the real number of ruptured de novo AVMs is underrepresented, since such lesions presenting with acute hemorrhage in patients that have never undergone a previous CT or MRI scan are automatically labeled as congenital in nature.
It must be noted that all of the diagnoses of de novo AVMs were made in conjunction with a previous associated pathology or injury. Had this not been the case, imaging studies prior to the symptomatic manifestation of the acquired AVMs would have been unnecessary, and the initial absence of these vascular lesions could not have been documented. Patients who experience seizures with or without apparent underlying causes, hemorrhagic or ischemic strokes, TBI of varying severity, other cerebrovascular malformations, or highly vascular tumors should receive regular imaging screening which includes DSA more often to highlight or exclude the formation of de novo AVMs. Further research should be conducted to more adequately ascertain the congenital or acquired characteristic of brain AVMs.

Funding

No funding was received for this research.

Institutional Review Board Statement

Ethical review and approval were waived for this study, due to it being a systematic review of the literature and it does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent Statement

Not applicable.

Acknowledgments

The authors would like to address their thanks to M. Horatiu Stan for his invaluable insight during the concept and preparation of this manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Florian, I.A.; Stan, H.M.; Florian, I.; Cheptea, M.; Berindan-Neagoe, I. Prognostic Factors in the Neurosurgical Treatment of Cerebral Arteriovenous Malformations. In World Federation of Neurosurgical Societies Symposia 2018 Proceeding Book; Kandasamy, R., Ed.; Editografica: Bolognia, Italy, 2019; pp. 232–241. [Google Scholar]
  2. Florian, I.S.; Baritchii, A.; Trifoi, S. Arterio-venous Mallformations. In Tratat de Chirurgie, 2nd ed.; Popescu, I., Ciuce, C., Eds.; Editura Academiei Romane: Cluj-Napoca, Romania, 2014; Volume 6, pp. 402–410. [Google Scholar]
  3. Florian, I.S.; Perju-Dumbravă, L. (Eds.) Therapeutic Options in Hemorrhagic Strokes; Editura Medicală Universitară, Iuliu Hațieganu: Cluj-Napoca, Romania, 2007; pp. 331–346. [Google Scholar]
  4. Kalb, S.; Gross, B.A.; Nakaji, P. 20-Vascular Malformations (Arteriovenous Malformations and Dural Arteriovenous Fistulas). In Principles of Neurological Surgery, 4th ed.; Content Repository Only: Philadelphia, PA, USA, 2018. [Google Scholar]
  5. Dalton, A.; Dobson, G.; Prasad, M.; Mukerji, N. De novo intracerebral arteriovenous malformations and a review of the theories of their formation. Br. J. Neurosurg. 2018, 32, 305–311. [Google Scholar] [CrossRef]
  6. Morales-Valero, S.F.; Bortolotti, C.; Sturiale, C.; Lanzino, G. Are parenchymal AVMs congenital lesions? Neurosurg. Focus 2014, 37, E2. [Google Scholar] [CrossRef]
  7. Tasiou, A.; Tzerefos, C.; Alleyne, C.H., Jr.; Boccardi, E.; Karlsson, B.; Kitchen, N.; Spetzler, R.F.; Tolias, C.M.; Fountas, K.N. Arteriovenous Malformations: Congenital or Acquired Lesions? World Neurosurg. 2020, 134, e799–e807. [Google Scholar] [CrossRef]
  8. Chen, Y.; Li, Z.; Shi, Y.; Huang, G.; Chen, L.; Tan, H.; Wang, Z.; Yin, C.; Hu, J. Deep Sequencing of Small RNAs in Blood of Patients with Brain Arteriovenous Malformations. World Neurosurg. 2018, 115, e570–e579. [Google Scholar] [CrossRef] [PubMed]
  9. Huang, J.; Song, J.; Qu, M.; Wang, Y.; An, Q.; Song, Y.; Yan, W.; Wang, B.; Wang, X.; Zhang, S.; et al. MicroRNA-137 and microRNA-195* inhibit vasculogenesis in brain arteriovenous malformations. Ann. Neurol. 2017, 82, 371–384. [Google Scholar] [CrossRef]
  10. Weinsheimer, S.; Bendjilali, N.; Nelson, J.; Guo, D.E.; Zaroff, J.G.; Sidney, S.; Mcculloch, C.E.; Al-Shahi Salman, R.; Berg, J.N.; Koeleman, B.P.; et al. Genome-wide association study of sporadic brain arteriovenous malformations. J. Neurol. Neurosurg. Psychiatry 2016, 87, 916–923. [Google Scholar] [CrossRef] [PubMed]
  11. Johnson, D.W.; Berg, J.N.; Baldwin, M.A.; Gallione, C.J.; Marondel, I.; Yoon, S.J.; Stenzel, T.T.; Speer, M.; Pericak-Vance, M.A.; Diamond, A.; et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet. 1996, 13, 189–195. [Google Scholar] [CrossRef] [PubMed]
  12. Mcallister, K.A.; Grogg, K.M.; Johnson, D.W.; Gallione, C.J.; Baldwin, M.A.; Jackson, C.E.; Helmbold, E.A.; Markel, D.S.; Mckinnon, W.C.; Murrell, J.; et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 1994, 8, 345–351. [Google Scholar] [CrossRef] [Green Version]
  13. Gallione, C.J.; Repetto, G.M.; Legius, E.; Rustgi, A.K.; Schelley, S.L.; Tejpar, S.; Mitchell, G.; Drouin, E.; Westermann, C.J.; Marchuk, D.A. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004, 363, 852–859. [Google Scholar] [CrossRef]
  14. Garrido-Martin, E.M.; Nguyen, H.L.; Cunningham, T.A.; Choe, S.W.; Jiang, Z.; Arthur, H.M.; Lee, Y.J.; Oh, S.P. Common and distinctive pathogenetic features of arteriovenous malformations in hereditary hemorrhagic telangiectasia 1 and hereditary hemorrhagic telangiectasia 2 animal models--brief report. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 2232–2236. [Google Scholar] [CrossRef] [Green Version]
  15. Park, S.O.; Wankhede, M.; Lee, Y.J.; Choi, E.J.; Fliess, N.; Choe, S.W.; Oh, S.H.; Walter, G.; Raizada, M.K.; Sorg, B.S.; et al. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J. Clin. Investig. 2009, 119, 3487–3496. [Google Scholar] [CrossRef] [PubMed]
  16. Han, C.; Choe, S.; Kim, Y.H.; Acharya, A.P.; Keselowsky, B.G.; Sorg, B.S.; Lee, Y.-J.; Oh, S.P. VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis 2014, 17, 823–830. [Google Scholar] [CrossRef]
  17. Bameri, O.; Salarzaei, M.; Parooie, F. KRAS/BRAF mutations in brain arteriovenous malformations: A systematic review and meta-analysis. Interv. Neuroradiol. 2021. [Google Scholar] [CrossRef] [PubMed]
  18. Goss, J.A.; Huang, A.Y.; Smith, E.; Konczyk, D.J.; Smits, P.J.; Sudduth, C.L.; Stapleton, C.; Patel, A.; Alexandrescu, S.; Warman, M.L.; et al. Somatic mutations in intracranial arteriovenous malformations. PLoS ONE 2019, 14, e0226852. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Priemer, D.S.; Vortmeyer, A.O.; Zhang, S.; Chang, H.Y.; Curless, K.L.; Cheng, L. Activating KRAS mutations in arteriovenous malformations of the brain: Frequency and clinicopathologic correlation. Hum. Pathol. 2019, 89, 33–39. [Google Scholar] [CrossRef] [PubMed]
  20. Pawlikowska, L.; Tran, M.N.; Achrol, A.S.; Ha, C.; Burchard, E.; Choudhry, S.; Zaroff, J.; Lawton, M.T.; Castro, R.; Mcculloch, C.E.; et al. Polymorphisms in transforming growth factor-beta-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations. Stroke 2005, 36, 2278–2280. [Google Scholar] [CrossRef] [Green Version]
  21. Simon, M.; Franke, D.; Ludwig, M.; Aliashkevich, A.F.; Köster, G.; Oldenburg, J.; Boström, A.; Ziegler, A.; Schramm, J. Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system. J. Neurosurg. 2006, 104, 945–949. [Google Scholar] [CrossRef]
  22. Kim, H.; Hysi, P.G.; Pawlikowska, L.; Poon, A.; Burchard, E.G.; Zaroff, J.G.; Sidney, S.; Ko, N.U.; Achrol, A.S.; Lawton, M.T.; et al. Common variants in interleukin-1-Beta gene are associated with intracranial hemorrhage and susceptibility to brain arteriovenous malformation. Cerebrovasc. Dis. 2009, 27, 176–182. [Google Scholar] [CrossRef] [Green Version]
  23. Chen, H.; Gu, Y.; Wu, W.; Chen, D.; Li, P.; Fan, W.; Lu, D.; Zhao, F.; Qiao, N.; Qiu, H.; et al. Polymorphisms of the vascular endothelial growth factor A gene and susceptibility to sporadic brain arteriovenous malformation in a Chinese population. J. Clin. Neurosci. 2011, 18, 549–553. [Google Scholar] [CrossRef]
  24. Pabaney, A.H.; Rammo, R.A.; Tahir, R.A.; Seyfried, D. Development of De Novo Arteriovenous Malformation Following Ischemic Stroke: Case Report and Review of Current Literature. World Neurosurg. 2016, 96, 608.e5–608.e12. [Google Scholar] [CrossRef] [PubMed]
  25. Dogan, S.N.; Bagcilar, O.; Mammadov, T.; Kizilkilic, O.; Islak, C.; Kocer, N. De Novo Development of a Cerebral Arteriovenous Malformation: Case Report and Review of the Literature. World Neurosurg. 2019, 126, 257–260. [Google Scholar] [CrossRef]
  26. Torres-Quinones, C.; Koch, M.J.; Raymond, S.B.; Patel, A. Left Thalamus Arteriovenous Malformation Secondary to Radiation Therapy of Original Vermian Arteriovenous Malformation: Case Report. J. Stroke Cerebrovasc. Dis. 2019, 28, e53–e59. [Google Scholar] [CrossRef]
  27. Lo Presti, A.; Rogers, J.M.; Assaad, N.N.A.; Rodriguez, M.L.; Stoodley, M.A.; Morgan, M.K. De novo brain arteriovenous malformation after tumor resection: Case report and literature review. Acta Neurochir. 2018, 160, 2191–2197. [Google Scholar] [CrossRef] [PubMed]
  28. Rodrigues De Oliveira, L.F.; Castro-Afonso, L.H.; Freitas, R.K.; Colli, B.O.; Abud, D.G. De Novo Intracranial Arteriovenous Malformation-Case Report and Literature Review. World Neurosurg. 2020, 138, 349–351. [Google Scholar] [CrossRef] [PubMed]
  29. Gonzalez, L.F.; Bristol, R.E.; Porter, R.W.; Spetzler, R.F. De novo presentation of an arteriovenous malformation. Case report and review of the literature. J. Neurosurg. 2005, 102, 726–729. [Google Scholar] [CrossRef] [PubMed]
  30. Mohr, J.P.; Yaghi, S. Management of unbled brain arteriovenous malformation study. Neurol. Clin. 2015, 33, 347–359. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Solomon, R.A.; Connolly, E.S., Jr. Arteriovenous Malformations of the Brain. N. Engl. J. Med. 2017, 377, 498. [Google Scholar] [CrossRef] [Green Version]
  32. Song, J.K.; Niimi, Y.; Kupersmith, M.J.; Berenstein, A. Postnatal growth and development of a cerebral arteriovenous malformation on serial magnetic resonance imaging in a child with hemangiomatosis. Case report. J. Neurosurg. 2007, 106, 384–387. [Google Scholar]
  33. Mendelow, A.D.; Erfurth, A.; Grossart, K.; Macpherson, P. Do cerebral arteriovenous malformations increase in size? J. Neurol. Neurosurg. Psychiatry 1987, 50, 980–987. [Google Scholar] [CrossRef] [PubMed]
  34. Du, R.; Hashimoto, T.; Tihan, T.; Young, W.L.; Perry, V.; Lawton, M.T. Growth and regression of arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia. Case report. J. Neurosurg. 2007, 106, 470–477. [Google Scholar] [CrossRef] [Green Version]
  35. Yeo, J.J.; Low, S.Y.; Seow, W.T.; Low, D.C. Pediatric de novo cerebral AVM: Report of two cases and review of literature. Childs Nerv. Syst. 2015, 31, 609–614. [Google Scholar] [CrossRef]
  36. Ozsarac, M.; Aksay, E.; Kiyan, S.; Unek, O.; Gulec, F.F. De novo cerebral arteriovenous malformation: Pink Floyd’s song “Brick in the Wall” as a warning sign. J. Emerg. Med. 2012, 43, e17–e20. [Google Scholar] [CrossRef]
  37. Harris, O.A.; Chang, S.D.; Harris, B.T.; Adler, J.R. Acquired cerebral arteriovenous malformation induced by an anaplastic astrocytoma: An interesting case. Neurol. Res. 2000, 22, 473–477. [Google Scholar] [CrossRef]
  38. Mckinney, J.S.; Steineke, T.; Nochlin, D.; Brisman, J.L. De novo formation of large arteriovenous shunting and a vascular nidus mimicking an arteriovenous malformation within an anaplastic oligodendroglioma: Treatment with embolization and resection. J. Neurosurg. 2008, 109, 1098–1102. [Google Scholar] [CrossRef] [PubMed]
  39. Mahajan, A.; Manchandia, T.C.; Gould, G.; Bulsara, K.R. De novo arteriovenous malformations: Case report and review of the literature. Neurosurg. Rev. 2010, 33, 115–119. [Google Scholar] [CrossRef]
  40. Akimoto, H.; Komatsu, K.; Kubota, Y. Symptomatic de novo arteriovenous malformation appearing 17 years after the resection of two other arteriovenous malformations in childhood: Case report. Neurosurgery 2003, 52, 228–231; discussion 231–232. [Google Scholar] [PubMed]
  41. Kawashima, M.; Hasegawa, H.; Kurita, H.; Suzuki, K.; Shin, M.; Ikemura, M.; Saito, N. Ectopic Recurrence of Arteriovenous Malformation After Radiosurgery: Case Report and Insight Regarding Pathogenesis. World Neurosurg. 2020, 135, 63–67. [Google Scholar] [CrossRef]
  42. Nussbaum, E.S.; Heros, R.C.; Madison, M.T.; Awasthi, D.; Truwit, C.L. The pathogenesis of arteriovenous malformations: Insights provided by a case of multiple arteriovenous malformations developing in relation to a developmental venous anomaly. Neurosurgery 1998, 43, 347–351; discussion 351–352. [Google Scholar] [CrossRef] [PubMed]
  43. Nagm, A.; Horiuchi, T.; Ichinose, S.; Hongo, K. Unique double recurrence of cerebral arteriovenous malformation. Acta Neurochir. 2015, 157, 1461–1466. [Google Scholar] [CrossRef]
  44. Koch, M.J.; Agarwalla, P.K.; Stapleton, C.J.; Ogilvy, C.S.; Loeffler, J.S. De novo development of a cerebral arteriovenous malformation following radiation therapy: Case report and an update to classical arteriovenous malformation nomenclature. J. Clin. Neurosci. 2016, 28, 162–167. [Google Scholar] [CrossRef]
  45. Shi, S.; Gupta, R.; Moore, J.M.; Griessenauer, C.J.; Adeeb, N.; Motiei-Langroudi, R.; Thomas, A.J.; Ogilvy, C.S. De novo AVM formation following venous sinus thrombosis and prior AVM resection in adults: Report of 2 cases. J. Neurosurg. 2018, 128, 506–510. [Google Scholar] [CrossRef] [Green Version]
  46. Shimoda, Y.; Osanai, T.; Nakayama, N.; Ushikoshi, S.; Hokari, M.; Shichinohe, H.; Abumiya, T.; Kazumata, K.; Houkin, K. De novo arteriovenous malformation in a patient with hereditary hemorrhagic telangiectasia. J. Neurosurg. Pediatr. 2016, 17, 330–335. [Google Scholar] [CrossRef] [Green Version]
  47. Zhou, D.; Huang, X.; Xie, Y.; Deng, Z.; Guo, J.; Huang, H. Astrocytes-derived VEGF exacerbates the microvascular damage of late delayed RBI. Neuroscience 2019, 408, 14–21. [Google Scholar] [CrossRef]
  48. Zhou, G.; Xu, Y.; He, B.; Ma, R.; Wang, Y.; Chang, Y.; Xie, Y.; Wu, L.; Huang, J.; Xiao, Z. Ionizing radiation modulates vascular endothelial growth factor expression through STAT3 signaling pathway in rat neonatal primary astrocyte cultures. Brain Behav. 2020, 10, e01529. [Google Scholar] [CrossRef] [PubMed]
  49. Alvarez, H.; Perry, V.; Solle, M.; Castillo, M. De novo cerebral arteriovenous malformation in a child with previous cavernous malformation and developmental venous anomaly. J. Neurosurg. Pediatr. 2012, 9, 327–330. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Lopez-Rivera, V.; Sheriff, F.G.; Sandberg, D.I.; Blackburn, S.; Dannenbaum, M.; Sheth, S.A.; Day, A.L.; Chen, P.R. De novo thalamic arteriovenous malformation in a boy with a brainstem cavernous malformation. J. Clin. Neurosci. 2020, 76, 226–228. [Google Scholar] [CrossRef] [PubMed]
  51. Leblanc, G.G.; Golanov, E.; Awad, I.A.; Young, W.L. Biology of vascular malformations of the brain. Stroke 2009, 40, e694–e702. [Google Scholar] [CrossRef] [Green Version]
  52. Sure, U.; Butz, N.; Schlegel, J.; Siegel, A.M.; Wakat, J.P.; Mennel, H.D.; Bien, S.; Bertalanffy, H. Endothelial proliferation, neoangiogenesis, and potential de novo generation of cerebrovascular malformations. J. Neurosurg. 2001, 94, 972–977. [Google Scholar] [CrossRef] [Green Version]
  53. Bai, Y.; He, C.; Zhang, H.; Ling, F. De novo multiple dural arteriovenous fistulas and arteriovenous malformation after embolization of cerebral arteriovenous fistula: Case report. Childs Nerv. Syst. 2012, 28, 1981–1983. [Google Scholar] [CrossRef]
  54. Friedman, J.A.; Pollock, B.E.; Nichols, D.A. Development of a cerebral arteriovenous malformation documented in an adult by serial angiography. Case report. J. Neurosurg. 2000, 93, 1058–1061. [Google Scholar] [CrossRef] [PubMed]
  55. Shidoh, S.; Kobayashi, M.; Akaji, K.; Kano, T.; Tanizaki, Y.; Mihara, B. De Novo Arteriovenous Malformation after Aneurysm Clipping. NMC Case Rep. J. 2017, 4, 89–92. [Google Scholar] [CrossRef] [Green Version]
  56. Miyasaka, Y.; Nakahara, K.; Takagi, H.; Hagiwara, H. Development of multiple cerebral arteriovenous malformations documented in an adult by serial angiography. Case report. J. Neurosurg. 2003, 98, 190–193. [Google Scholar] [CrossRef] [Green Version]
  57. Porter, A.J.; Bull, J. Some aspects of the natural history of cerebral arteriovenous malformation. Br. J. Radiol. 1969, 42, 667–675. [Google Scholar] [CrossRef]
  58. Peeters, F.L. Angiographically demonstrated larger vascular malformation in a patient with a normal angiogram 23 years before. Neuroradiology 1982, 23, 113–114. [Google Scholar] [CrossRef] [PubMed]
  59. Fuse, T.; Niwa, Y.; Umezu, M.; Yamada, K. Growth of occult arteriovenous malformation after cerebral hemorrhage demonstrated by serial magnetic resonance imaging—Case report. Neurol. Med. Chir. 2001, 41, 83–86. [Google Scholar] [CrossRef] [Green Version]
  60. Jeffree, R.L.; Stoodley, M.A. Postnatal development of arteriovenous malformations. Pediatr. Neurosurg. 2009, 45, 296–304. [Google Scholar] [CrossRef]
  61. Morioka, T.; Nishio, S.; Hikita, T.; Chung, L.H.; Soejima, T. Marked growth of an angiographically occult arteriovenous malformation: Case report. Neurosurgery 1988, 23, 101–103. [Google Scholar] [CrossRef] [PubMed]
  62. Nakamura, M.; Samii, A.; Lang, J.M.; Götz, F.; Samii, M.; Krauss, J.K. De Novo Arteriovenous Malformation Growth Secondary to Implantation of Genetically Modified Allogeneic Mesenchymal Stem Cells in the Brain. Neurosurgery 2016, 78, E596–E600. [Google Scholar] [CrossRef]
  63. Nakamura, M.; Krauss, J.K. In Reply: De Novo Arteriovenous Malformation Growth Secondary to Implantation of Genetically Modified Allogeneic Mesenchymal Stem Cells in the Brain. Neurosurgery 2016, 78, E602–E603. [Google Scholar] [CrossRef]
  64. Kilbourn, K.J.; Spiegel, G.; Killory, B.D.; Kureshi, I. Case report of a de novo brainstem arteriovenous malformation in an 18-year-old male and review of the literature. Neurosurg. Rev. 2014, 37, 685–691. [Google Scholar] [CrossRef]
  65. Laura, K.; Markham, M.A.H. De Novo Arteriovenous Malformation in a 4 Year-Old Boy with Headache, with No Previous Cerebrovascular Disease. J. Neurol. Neurosci. 2015, 6, 3. [Google Scholar]
  66. Neil, J.A.; Li, D.; Stiefel, M.F.; Hu, Y.C. Symptomatic de novo arteriovenous malformation in an adult: Case report and review of the literature. Surg. Neurol. Int. 2014, 5, 148. [Google Scholar]
  67. Stevens, J.; Leach, J.L.; Abruzzo, T.; Jones, B.V. De novo cerebral arteriovenous malformation: Case report and literature review. Am. J. Neuroradiol. 2009, 30, 111–112. [Google Scholar] [CrossRef]
  68. Wu, J.; Li, Y.; Cao, Y.; Wang, S. De novo cerebral arteriovenous malformations: Is epileptic seizure a potential trigger? Childs Nerv. Syst. 2014, 30, 1277–1281. [Google Scholar] [CrossRef]
  69. Abecassis, I.J.; Xu, D.S.; Batjer, H.H.; Bendok, B.R. Natural history of brain arteriovenous malformations: A systematic review. Neurosurg. Focus 2014, 37, E7. [Google Scholar] [CrossRef] [PubMed]
  70. Castillo, M.; Thompson, J.E.; Mukherji, S.K. Association of an intracranial arteriovenous malformation and a meningioma. Neuroradiology 1998, 40, 574–576. [Google Scholar] [CrossRef] [PubMed]
  71. Croll, S.D.; Goodman, J.H.; Scharfman, H.E. Vascular endothelial growth factor (VEGF) in seizures: A double-edged sword. Adv. Exp. Med. Biol. 2004, 548, 57–68. [Google Scholar]
  72. Sun, F.J.; Wei, Y.J.; Li, S.; Guo, W.; Chen, X.; Liu, S.Y.; He, J.J.; Yin, Q.; Yang, H.; Zhang, C.Q. Elevated Expression of VEGF-C and Its Receptors, VEGFR-2 and VEGFR-3, in Patients with Mesial Temporal Lobe Epilepsy. J. Mol. Neurosci. 2016, 59, 241–250. [Google Scholar] [CrossRef] [PubMed]
  73. Vezzani, A. VEGF and seizures: Cross-talk between endothelial and neuronal environments. Epilepsy Curr. 2005, 5, 72–74. [Google Scholar] [CrossRef] [PubMed]
  74. Castañeda-Cabral, J.L.; Beas-Zárate, C.; Rocha-Arrieta, L.L.; Orozco-Suárez, S.A.; Alonso-Vanegas, M.; Guevara-Guzmán, R.; Ureña-Guerrero, M.E. Increased protein expression of VEGF-A, VEGF-B, VEGF-C and their receptors in the temporal neocortex of pharmacoresistant temporal lobe epilepsy patients. J. Neuroimmunol. 2019, 328, 68–72. [Google Scholar] [CrossRef]
  75. Lange, C.; Storkebaum, E.; De Almodóvar, C.R.; Dewerchin, M.; Carmeliet, P. Vascular endothelial growth factor: A neurovascular target in neurological diseases. Nat. Rev. Neurol. 2016, 12, 439–454. [Google Scholar] [CrossRef]
  76. Nicoletti, J.N.; Lenzer, J.; Salerni, E.A.; Shah, S.K.; Elkady, A.; Khalid, S.; Quinteros, D.; Rotella, F.; Betancourth, D.; Croll, S.D. Vascular endothelial growth factor attenuates status epilepticus-induced behavioral impairments in rats. Epilepsy Behav. 2010, 19, 272–277. [Google Scholar] [CrossRef] [Green Version]
  77. Ureña-Guerrero, M.E.; Castañeda-Cabral, J.L.; Rivera-Cervantes, M.C.; Macias-Velez, R.J.; Jarero-Basulto, J.J.; Gudiño-Cabrera, G.; Beas-Zárate, C. Neuroprotective and Neurorestorative Effects of Epo and VEGF: Perspectives for New Therapeutic Approaches to Neurological Diseases. Curr. Pharm. Des. 2020, 26, 1263–1276. [Google Scholar] [CrossRef]
  78. Franco, A.; Pimentel, J.; Campos, A.R.; Morgado, C.; Pinelo, S.; Ferreira, A.G.; Bentes, C. Stimulation of the bilateral anterior nuclei of the thalamus in the treatment of refractory epilepsy: Two cases of subcortical band heterotopia. Epileptic. Disord. 2016, 18, 426–430. [Google Scholar] [CrossRef]
  79. Parrini, E.; Conti, V.; Dobyns, W.B.; Guerrini, R. Genetic Basis of Brain Malformations. Mol. Syndromol. 2016, 7, 220–233. [Google Scholar] [CrossRef] [Green Version]
  80. Sahu, S.; Buhler, E.; Vermoyal, J.C.; Watrin, F.; Represa, A.; Manent, J.B. Spontaneous epileptiform activity in a rat model of bilateral subcortical band heterotopia. Epilepsia 2019, 60, 337–348. [Google Scholar] [CrossRef] [Green Version]
  81. Borges, L.R.; Malheiros, S.M.; Pelaez, M.P.; Stávale, J.N.; Santos, A.J.; Carrete, H., Jr.; Nogueira, R.G.; Ferraz, F.A.; Gabbai, A.A. Arteriovenous malformation-glioma association: Study of four cases. Arq. Neuropsiquiatr. 2003, 61, 426–429. [Google Scholar] [CrossRef] [Green Version]
  82. Goodkin, R.; Zaias, B.M.; Michelsen, W.J. Arteriovenous malformation and glioma: Coexistent or sequential? Case report. J. Neurosurg. 1990, 72, 798–805. [Google Scholar] [CrossRef]
  83. Soria, E.; Fine, E.; Hajdu, I. Association of intracranial meningioma with arteriovenous malformation. Surg. Neurol. 1990, 34, 111–117. [Google Scholar] [CrossRef]
  84. Suzuki, H.; Uenohara, H.; Utsunomiya, A.; Kurihara, N.; Suzuki, S.; Tadokoro, M.; Iwasaki, Y.; Sakurai, Y.; Takei, H.; Tezuka, F. A case of angioglioma composed of astrocytoma with a papillary growth pattern: Immunohistochemical and ultrastructural studies. Brain Tumor Pathol. 2002, 19, 111–116. [Google Scholar] [CrossRef] [PubMed]
  85. Bennett, E.E.; Otvos, B.; Kshettry, V.R.; Gonzalez-Martinez, J. Delayed presentation of an arteriovenous malformation after cerebellar hemangioblastoma resection-Case report. Int. J. Surg. Case Rep. 2016, 23, 47–51. [Google Scholar] [CrossRef] [Green Version]
  86. Mathon, B.; Blauwblomme, T.; Bolle, S.; Dufour, C.; Nagarra, O.; Brunelle, F.; Puget, S. De novo arteriovenous malformation after brain radiotherapy for medulloblastoma in a child. Neurology 2013, 81, 398–399. [Google Scholar] [CrossRef] [Green Version]
  87. Medvedev, Y.A.; Matsko, D.E.; Zubkov, Y.N.; Pak, V.A.; Alexander, L.F. Coexistent hemangioblastoma and arteriovenous malformation of the cerebellum. Case report. J. Neurosurg. 1991, 75, 121–125. [Google Scholar] [CrossRef] [PubMed]
  88. Kaido, T.; Hoshida, T.; Uranishi, R.; Akita, N.; Kotani, A.; Nishi, N.; Sakaki, T. Radiosurgery-induced brain tumor. Case report. J. Neurosurg. 2001, 95, 710–713. [Google Scholar] [CrossRef] [PubMed]
  89. Koshimura, I.; Takeda, N.; Ohtomo, T.; Shimada, J.; Sugano, K.; Mori, H.; Mizuno, Y.; Sato, K. A 32-year-old man who developed a posterior fossa mass 12 years after the radiation therapy for cerebellar arteriovenous malformation. No Shinkei 1996, 48, 81–89. [Google Scholar]
  90. Wolf, A.; Naylor, K.; Tam, M.; Habibi, A.; Novotny, J.; Liščák, R.; Martinez-Moreno, N.; Martinez-Alvarez, R.; Sisterson, N.; Golfinos, J.G.; et al. Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: A retrospective, multicentre, cohort study. Lancet Oncol. 2019, 20, 159–164. [Google Scholar] [CrossRef]
  91. Dore-Duffy, P.; Lamanna, J.C. Physiologic angiodynamics in the brain. Antioxid. Redox Signal. 2007, 9, 1363–1371. [Google Scholar] [CrossRef]
  92. Santos, R.; Aguilar-Salinas, P.; Entwistle, J.J.; Aldana, P.R.; Beier, A.D.; Hanel, R.A. De Novo Arteriovenous Malformation in a Pediatric Patient: Case Report and Review of the Literature. World Neurosurg. 2018, 111, 341–345. [Google Scholar] [CrossRef]
  93. Komiyama, M. Revised perspective of cerebral arteriovenous malformation. Jpn. J. Neurosurg. 2011, 20, 4–11. [Google Scholar] [CrossRef] [Green Version]
  94. Ozawa, T.; Miyasaka, Y.; Tanaka, R.; Kurata, A.; Fujii, K. Dural-pial arteriovenous malformation after sinus thrombosis. Stroke 1998, 29, 1721–1724. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Fujimura, M.; Kimura, N.; Ezura, M.; Niizuma, K.; Uenohara, H.; Tominaga, T. Development of a de novo arteriovenous malformation after bilateral revascularization surgery in a child with moyamoya disease. J. Neurosurg. Pediatr. 2014, 13, 647–649. [Google Scholar] [CrossRef] [Green Version]
  96. Noh, J.H.; Yeon, J.Y.; Park, J.H.; Shin, H.J. Cerebral arteriovenous malformation associated with moyamoya disease. J. Korean Neurosurg. Soc. 2014, 56, 356–360. [Google Scholar] [CrossRef]
  97. O’shaughnessy, B.A.; Dipatri, A.J., Jr.; Parkinson, R.J.; Batjer, H.H. Development of a de novo cerebral arteriovenous malformation in a child with sickle cell disease and moyamoya arteriopathy. Case report. J. Neurosurg. 2005, 102, 238–243. [Google Scholar] [CrossRef]
  98. Schmit, B.P.; Burrows, P.E.; Kuban, K.; Goumnerova, L.; Scott, R.M. Acquired cerebral arteriovenous malformation in a child with moyamoya disease. Case report. J. Neurosurg. 1996, 84, 677–680. [Google Scholar] [CrossRef]
  99. Kayama, T.; Suzuki, S.; Sakurai, Y.; Nagayama, T.; Ogawa, A.; Yoshimoto, T. A case of moyamoya disease accompanied by an arteriovenous malformation. Neurosurgery 1986, 18, 465–468. [Google Scholar] [CrossRef]
  100. Mawad, M.E.; Hilal, S.K.; Michelsen, W.J.; Stein, B.; Ganti, S.R. Occlusive vascular disease associated with cerebral arteriovenous malformations. Radiology 1984, 153, 401–408. [Google Scholar] [CrossRef] [PubMed]
  101. Montanera, W.; Marotta, T.R.; Terbrugge, K.G.; Lasjaunias, P.; Willinsky, R.; Wallace, M.C. Cerebral arteriovenous malformations associated with moyamoya phenomenon. Am. J. Neuroradiol. 1990, 11, 1153–1156. [Google Scholar] [PubMed]
  102. Anami, H.; Aihara, Y.; Kawashima, A.; Yamaguchi, K.; Nagahara, A.; Okada, Y. A case report of a pediatric traumatic aneurysm with arteriovenous (A-V) fistula CASE-BASED UPDATE. Childs Nerv. Syst. 2014, 30, 2003–2008. [Google Scholar] [CrossRef] [PubMed]
  103. Cuoco, J.A.; Guilliams, E.L.; Klein, B.J.; Malaty, G.R.; Witcher, M.R.; Entwistle, J.J. N-butyl cyanoacrylate embolization of a traumatic pseudoaneurysm and arteriovenous fistula of the middle meningeal artery. Radiol. Case Rep. 2020, 15, 321–325. [Google Scholar] [CrossRef] [PubMed]
  104. Tokairin, K.; Osanai, T.; Kazumata, K.; Sawaya, R.; Houkin, K. Contrecoup Injury-Induced Middle Meningeal Arteriovenous Fistula Detected by Time-of-Flight Magnetic Resonance Angiography and Magnetic Resonance Arterial Spin Labeling: Case Report and Review of the Literature. World Neurosurg. 2019, 127, 79–84. [Google Scholar] [CrossRef]
  105. Miller, B.A.; Bass, D.I.; Chern, J.J. Development of a de novo arteriovenous malformation after severe traumatic brain injury. J. Neurosurg. Pediatr. 2014, 14, 418–420. [Google Scholar] [CrossRef] [Green Version]
  106. Krayenbühl, H.A. Angiographic contribution to the problem of enlargement of cerebral arteriovenous malformations. Acta Neurochir. 1977, 36, 215–242. [Google Scholar] [CrossRef]
  107. Dotan, M.; Lorber, A. Congestive heart failure with diffuse neonatal hemangiomatosis—Case report and literature review. Acta Paediatr. 2013, 102, e232–e238. [Google Scholar] [CrossRef]
  108. Patiroglu, T.; Sarici, D.; Unal, E.; Yikilmaz, A.; Tucer, B.; Karakukcu, M.; Ozdemir, M.A.; Canoz, O.; Akcakus, M. Cerebellar hemangioblastoma associated with diffuse neonatal hemangiomatosis in an infant. Childs Nerv. Syst. 2012, 28, 1801–1805. [Google Scholar] [CrossRef]
  109. Bulsara, K.R.; Alexander, M.J.; Villavicencio, A.T.; Graffagnino, C. De novo cerebral arteriovenous malformation: Case report. Neurosurgery 2002, 50, 1137–1140; discussion 1140–1141. [Google Scholar]
  110. Gondar, R.; El Rahal, A.; Kulcsár, Z.; Schaller, K.; Momjian, S. Spontaneous appearance of de novo intracranial arteriovenous malformation in hepatic cirrhosis. Neurochirurgie 2019, 65, 393–396. [Google Scholar] [CrossRef]
  111. Shimoda, Y.; Kuroda, S.; Kashiwazaki, D.; Asano, T.; Yamashita, K.; Taniguchi, M.; Suzuki, T.; Shimamura, T.; Furukawa, H.; Nakayama, N.; et al. Spontaneous disappearance of intracranial arteriovenous malformation after living-donor liver transplantation: A case report. No Shinkei Geka 2011, 39, 589–594. [Google Scholar]
  112. Chen, W.; Sun, Z.; Han, Z.; Jun, K.; Camus, M.; Wankhede, M.; Mao, L.; Arnold, T.; Young, W.L.; Su, H. De novo cerebrovascular malformation in the adult mouse after endothelial Alk1 deletion and angiogenic stimulation. Stroke 2014, 45, 900–902. [Google Scholar] [CrossRef] [Green Version]
  113. Walker, E.J.; Su, H.; Shen, F.; Choi, E.J.; Oh, S.P.; Chen, G.; Lawton, M.T.; Kim, H.; Chen, Y.; Chen, W.; et al. Arteriovenous malformation in the adult mouse brain resembling the human disease. Ann. Neurol. 2011, 69, 954–962. [Google Scholar] [CrossRef] [PubMed]
  114. Zhu, W.; Saw, D.; Weiss, M.; Sun, Z.; Wei, M.; Shaligram, S.; Wang, S.; Su, H. Induction of Brain Arteriovenous Malformation Through CRISPR/Cas9-Mediated Somatic Alk1 Gene Mutations in Adult Mice. Transl. Stroke Res. 2019, 10, 557–565. [Google Scholar] [CrossRef]
  115. Fujii, M.; Ichikawa, M.; Iwatate, K.; Bakhit, M.; Yamada, M.; Kuromi, Y.; Sato, T.; Sakuma, J.; Sato, H.; Kikuta, A.; et al. Secondary brain tumors after cranial radiation therapy: A single-institution study. Rep. Pract. Oncol. Radiother. 2020, 25, 245–249. [Google Scholar] [CrossRef] [PubMed]
  116. Mariniello, G.; De Liso, M.; Russo, C.; Del Vecchio, W.; De Divitiis, O.; Bruno, F.; Maggialetti, N.; Arrigoni, F.; Brunese, L.; Caranci, F. Radiation-induced brain cavernomas in elderly: Review of the literature and a rare case report. Acta Biomed. 2019, 90, 77–83. [Google Scholar]
  117. Sheen, J.J.; Lee, D.H.; Lee, D.H.; Song, Y.; Kwon, D.H. Long-Term Outcome of Gamma Knife Radiosurgery for Brain Cavernoma: Factors Associated with Subsequent De Novo Cavernoma Formation. World Neurosurg. 2018, 120, e17–e23. [Google Scholar] [CrossRef]
  118. Isayama, Y.; Nakagawara, J.; Takeda, R.; Wada, K.; Hyogo, T.; Sasaki, T.; Nakamura, J.; Suematsu, K. A case of cerebral arteriovenous malformation revealed at repeated subcortical hematoma with initially normal angiogram. No Shinkei Geka 1991, 19, 1175–1180. [Google Scholar]
Medicina 57 00201 g001 550
Figure 1. Analytical flow-chart of the literature search process used.
Figure 1. Analytical flow-chart of the literature search process used.
Medicina 57 00201 g001
Medicina 57 00201 g002 550
Figure 2. Distribution of patients with de novo arteriovenous malformations according to gender and decade of age at the time of diagnosis. Abscissa: age group (decade of life) for male (dark grey) and female (light grey) patients. Ordinate: number of patients included.
Figure 2. Distribution of patients with de novo arteriovenous malformations according to gender and decade of age at the time of diagnosis. Abscissa: age group (decade of life) for male (dark grey) and female (light grey) patients. Ordinate: number of patients included.
Medicina 57 00201 g002
Medicina 57 00201 g003 550
Figure 3. Pathologies allegedly associated with de novo arteriovenous malformations, distributed in ascending order of frequency. Abscissa: total number of patients. Ordinate: associated pathology.
Figure 3. Pathologies allegedly associated with de novo arteriovenous malformations, distributed in ascending order of frequency. Abscissa: total number of patients. Ordinate: associated pathology.
Medicina 57 00201 g003
Medicina 57 00201 g004 550
Figure 4. Treatment methods utilized for de novo arteriovenous malformations.
Figure 4. Treatment methods utilized for de novo arteriovenous malformations.
Medicina 57 00201 g004
Medicina 57 00201 g005 550
Figure 5. Schematization of the “second hit” theory for the development of de novo arteriovenous malformations (AVM). Genetic susceptibility can be represented by syndromes such as hereditary hemorrhagic telangiectasia (HHT) or diffuse neonatal hemangiomatosis (DNT). After birth, a second may occur, leading to the formation of an acquired AVM after a variable point in time. This second hit can be a preexisting vascular lesion or malformation, hemorrhagic stroke, seizures, ischemic stroke, brain tumors, Moyamoya disease (MMD), traumatic brain injury (TBI), cirrhosis, or inflammatory lesions.
Figure 5. Schematization of the “second hit” theory for the development of de novo arteriovenous malformations (AVM). Genetic susceptibility can be represented by syndromes such as hereditary hemorrhagic telangiectasia (HHT) or diffuse neonatal hemangiomatosis (DNT). After birth, a second may occur, leading to the formation of an acquired AVM after a variable point in time. This second hit can be a preexisting vascular lesion or malformation, hemorrhagic stroke, seizures, ischemic stroke, brain tumors, Moyamoya disease (MMD), traumatic brain injury (TBI), cirrhosis, or inflammatory lesions.
Medicina 57 00201 g005
Table
Table 1. Illustrates each individual case reported, categorized according to the underlying pathology.
Table 1. Illustrates each individual case reported, categorized according to the underlying pathology.
AuthorsSexAge (yrs.)—De Novo AVMInitial SymptomsImaging (−)Associated PathologySymptoms—De NovoImaging (+)Diagnosis Interval (yrs.)AVM locationTreatmentOutcome
Akimoto et al., 2003F27Intraventricular hemorrhage (10 yrs. old)CTA
DSA		Splenium AVM & L Occipital AVM − ruptured + resectedHeadache, R sided numbnessCTA
DSA
MRI		17Cingulate gyrus & corpus callosumMSFavorable
Alvarez et al., 2012M8SeizuresCT
MRI		Giant R T-O cavernomaASXMRI
DSA		2PinealCFavorable
Bai et al., 2012M7Generalized tonic-clinic seizureMRI
DSA		Dural AVF, embolization; multiple dAVFs simultaneous with AVMSeizure relapseMRI
DSA		4L medial OccipitalEFavorable
de Oliveira et al., 2020F16HeadacheMRI
DSA		Ruptured R occipital cavernoma, operatedHeadacheMRI
DSA		10R TemporalE+MSFavorable
Friedman et al., 2000M68Vertigo and vomitingCT
DSA
MRI		R tentorial DAVF, treated via SRS and embolizationASX; 2 years later (age 70)-vertigo and nauseaCT
DSA
MRI		7Sup. VermisSRSFavorable
Kawashima et al., 2019F29Cerebellar hemorrhage, ataxiaCT
DSA
MRI		R cerebellar AVM, ruptured, treated with SRSheadache, vomiting, and worsened ataxiaCT
DSA
MRI		20R cerebellar, ectopicE+MSFavorable
Lopez-Rivera et al., 2020M6Midbrain hemorrhageMRI
DSA		Midbrain cavernoma, rupturedHeadachesMRI
DSA		2R ThalamusCN/S
Nagm et al., 2015F23Severe headache, seizuresDSAR frontal AVM, E+MS; ectopic recurrence, reoperatedASXMRI
DSA		18R Frontal, ectopicCN/S
Nussbaum et al., 1998M34Headache, vertigo, blurred visionDSAR cerebellar AVM, C treatmentRecurrence of headache and vertigoDSA10R cerebellar, ectopicEFavorable
Rodriguez-Arias, 2000F11SeizuresCT
DSA
MRI		R parietal AVM, treated via SRSASXMRI
DSA		2R Parietal (medial)SRSFavorable
Shi et al., 2018M72Gait instabilityCTA
DSA		L Frontal AVM (ruptured), resectedL HemianopsiaCTA
DSA		11R TemporooccipitalMSFavorable
Shidoh et al., 2016F73ASXDSAUnruptured R MCA aneurysm, clippedASXMRI
DSA		5R Parietal (postcentral)SRSFavorable
Torres-Quinones et al., 2019M80VertigoCT
DSA
MRI		R superior cerebellar aneurysm, hypertension, vermian AVM treated via radiosurgeryGait instabilityMRI
DSA		10L ThalamusN/SN/S
Fuse et al., 2001M23L hemiparesisCT
DSA		R frontal cerebral hemorrhageASXMRI
DSA		4R FrontalMSFavorable
Isayama et al., 1991M20Subcortical hemorrhageCT
DSA		L temporal subcortical hemorrhage, evacuated surgicallySecond L temporal hemorrhageDSA2L TemporalMSN/S
Jeffree et al., 2009M18Headache, facial droop, speech deficit, vomiting, LOCCT
DSA
MRI		L Parietal hematomaFacial droop, aphasia, vomiting, LOCCT
DSA		10R ParietooccipitalMSFavorable
Jeffree et al., 2009M15N/SDSAR temporo-parietal IPHASXDSA5R TemporoparietalMSFavorable
Jeffree et al., 2009M5Irritability, poor feeding, vomiting and jaundiceTUS
CT
MRI		R temporo-parietal IPH at 17 days after birthVomiting, episodes of LOCCT
DSA		5R Sylvian and basal gangliaSRSUnfavorable, died 3 months later
Lv et al., 2018F22IPHDSAHemorrhage from N/S causeSeizures and headachesMRI
DSA		4R ParietalN/SN/S
Mendelow et al., 1987N/SN/SSAHAngio.SAH of N/S originSAHAngio.14R OccipitalCN/S
Miyasaka et al., 2003F58Headache, vomiting, L hemiparesisCT
Angio.		R parietal IPHSevere headache, vomitingCT
DSA
MRI		8R Frontal, R Parietal, L OccipitalSRSN/S
Morioka et al., 1988M23SAH, LOCAngio.SAH of N/S originGeneralized seizures, postictal R hemiparesisCT
Angio.		7L FrontalMSFavorable
Nakamura et al., 2016M53L frontal IPHMRI
DSA		IPH, evacuated; local implantation of MSCs producing GLP-1Aphasia, focal seizures, new L frontal cerebral hemorrhageCTA
DSA		3L FrontalMSFavorable
Peeters, 1982M26SAHAngio.SAH of N/S originSeizuresAngio.23R FrontalN/SN/S
Porter and Bull, 1969M24SAHAngio.SAH of N/S originSAHAngio.2R OccipitalN/SN/S
Dogan et al., 2019M25Seizures, recurrentMRIR parietal parafalcine arachnoid cyst, seizuresRecurrent seizuresMRI
DSA		14L FrontalCN/S
Kilbourn et al., 2014M18N/SCT
MRI		HCP, absence seizures, autismHeadache, vomiting followed by LOCCTA
DSA
MRI		17PonsCN/S
Markham et al., 2015M4SeizuresMRISeizuresSevere headacheMRI
DSA		3L TemporalMSN/S
Neil et al., 2014M24SeizuresMRIEpilepsy and head traumaSeizuresMRI
DSA		9L ParietalE+MSFavorable
Ozsarac et al., 2012M50EpilepsyAngio.Generalized tonic-clonic seizuresAH (Pink Floyd’s “Another Brick in the Wall”)CTA25L TemporoparietalCN/S
Stevens et al., 2009F9Seizures, developmental delayMRISBH (L temporo-occipital)Seizures, behav. change, ataxia, and aphasiaCT
DSA
MRI		3L ParietooccipitalSRSN/S
Wu et al., 2014M7Fever, convulsionsMRIFebrile seizureSeizures, L visual scotomaMRI
DSA		4R OccipitalMSFavorable
Yeo et al., 2014F16Single episode of seizuresMRIEpileptic seizure of N/S causeIntermittent headachesMRI9L TemporalMSN/S
Yeo et al., 2014M7SeizuresMRIEpilepsyRecurrent seizuresMRI
DSA		6L cerebellarSRSN/S
Bennet et al., 2016F45headache, vertigo, nausea, vomitingCT
MRI		Vermian hemangioblastomaheadaches, dizzinessCTA
DSA
MRI		1L cerebellar (posterior)MSFavorable
Harris et al., 2000M57headaches, confusion, L sided weakness and numbnessCT
carotid Doppler
Angio.		R carotid stenosis, malignant R thalamic astrocytomaNausea, vomiting, weight lossMRI
Angio.		0,25R ThalamusBiopsy, SRSUnfavorable, died 4 months later
Koch et al., 2016F24developmental regressionMRI4th ventricle ependymoma, HCP, treatment with surgery + radiotherapyPartial complex seizureMRI
DSA		23L ChoroidalSRSN/S
Lo Presti et al., 2018F67Headaches, L frontal lumpCTRecurrent meningioma, operated, acrylic cranioplastyL pulsatile tinnitusMRI
DSA		7L FrontalMSFavorable
Mathon et al., 2013M9N/SMRI4th ventricle MB, operated, chemo+radioASXMRI
DSA		4R SylvianE+MSN/S
McKinney et al., 2008F58Transient L-sided weaknessMRIL thalamic hemorrhage; anaplastic ODG in the same regionL sided weakness, dysarthria, L visual field defectMRI
DSA		3R FrontoparietalMSUnfavorable, died on postop day 6
Morales-Valero et al., 2014M56TIADSATIA, cause N/STransient neurological eventDSA14L FrontalN/SN/S
Ozawa et al., 1998M39Headache, vomiting, weakness in L armCT
DSA
MRI		Thrombosis of SSS and R TSASXMRI
DSA		2R ParietalE+MSFavorable
Pabaney et al., 2016F52R hemiplegia and severe dysarthriaCTA
MRI		Acute L frontal ischemic strokeGeneralized tonic-clonic seizure, L frontal IPHCTA
DSA		8L FrontalMSN/S
Santos et al., 2018M7Mild L hemiparesisMRI
DSA		R PComA aneurysm, R hemispheric stroke;ASXDSA6R ThalamusCN/S
Shi et al., 2018F33HeadacheMRVL TS thrombosisASXMRI
DSA		2L TemporooccipitalCFavorable
Fujimura et al., 2014F14Weakness in upper limbsMRIMMD, bilateral revascularizationASXMRI
DSA		4R OccipitalCFavorable
Noh et al., 2014F15TIA on R sideMRI
DSA		MMDASXDSA8R Frontal interhemisphericCFavorable
O’Shaughnessy, 2005M6Infarction, dysphasia, R hemiparesisMRISS-disease, MMD, L frontal cerebral infarctionMild dysphasia, mild R hemiparesisMRI
DSA		3R SylvianMSFavorable
Schmidt et al., 1996M11R arm and leg weaknessCT
Angio.		MMD, infarctionASXMRI
DSA
SPECT		8L ParietalN/SN/S
Gonzalez et al., 2005F7Head traumaMRITraffic accident, L frontal hemorrhageUnremitting seizuresMRI
DSA		4R TemporalSRSFavorable
Krayenbuhl, 1977M12Headache, vomiting, stiffness of the neckAngio.SAH of N/S origin, from head traumaHeadache, LOC, meningeal irritationAngio.9R FrontalMSFavorable
Miller et al., 2014F12Head traumaCTSevere TBI, L SDH; cranioplastySeizures, increased frequencyMRI
DSA		11L ParietalMSFavorable
Shimoda et al., 2015M5ASX—screening for HHTMRIHHTRecurrent epistaxis, thunderclap headacheMRI
DSA		4R ParietalE+MSFavorable
Song et al., 2007F2,5Congestive heart failureMRICardiomegaly and CHF; hepatic hemangiomasIntermittent downward gaze, gait instability, DDMRI
DSA		2,5L CPAEInitially favorable; died at the age of 6 due to cerebral hemorrhage
Bulsara et al., 2002F32Intermittent monocular vision loss, ataxia, diplopia, ptosis, blurred vision, aphasia, gait disturbanceDSA
MRI
PET		Inflammation/demyelinating lesion in brainstem and diencephalonSevere headache, nausea, vomiting, ruptured AVMCTA
DSA
MRI		6R TemporalMSFavorable
Mahajan et al., 2009F30Facial nerve palsyMRIBell’s palsyMigraines, R-sided facial weakness, aphasiaCT
DSA
MRI		14L FrontoparietalN/SN/S
Gondar et al., 2019F57Mild head traumaMRICirrhosis, R pre-central DVA, TBI after alcohol poisoningGait imbalance dysarthria, L hemiparesisCT
DSA
MRI		2R Frontal precentralSRSUnfavorable, died 2 weeks later due to PE
Morales-Valero et al., 2014F35ConfusionMRILiver cirrhosis, PSEIPHMRI
DSA		4L ParietooccipitalN/SN/S
Reported cases of de novo AVMs in pediatric and adult patients, arranged according to probable correlated pathology. All patients included had an initial negative imaging study for the vascular malformation to have been labeled as ‘de novo.’ Imaging (−) reflects the initial negative study that did not show the presence of the AVM, whereas Imaging (+) signifies the study that revealed the later-diagnosed AVM. An ectopic label for the location of the de novo AVM denotes a lesion in the same general area as a previous lesion, but outside of the boundaries of that lesion. Abbreviations: AH, auditory hallucinations; Angio., angiography; AVM, arteriovenous malformation; ASX, asymptomatic; behav. change, behavioral change; C, conservative; chemo+radio, chemotherapy and radiotherapy; CHF, congestive heart failure; CPA, cerebellopontine angle; CT, computed tomography; CTA, computed tomography angiography; dAVF, dural arteriovenous fistula; DD, developmental delay; DSA, digital subtraction angiography; E, embolization; E+MS, embolization followed by surgical resection; GLP-1, glucagon-like peptide 1; HCP, hydrocephalus; HHT, hereditary hemorrhagic telangiectasia; IPH, intraparenchymal hemorrhage; L, Left; LOC, loss of consciousness; MB, medulloblastoma; MCA, middle cerebral artery; MMD, Moyamoya disease; MRI, magnetic resonance imaging; MRV, magnetic resonance venography; MS, microsurgical resection; MSC, mesenchymal stem cells; N/S, not specified; ODG, oligodendroglioma; PComA, posterior communicant artery; PE, pulmonary embolism; PSE, portosystemic encephalopathy; R, right; SAH, subarachnoid hemorrhage; SBH, subcortical band heterotopia; SDH, subdural hematoma; SRS, stereotactic radiosurgery; SS-disease, sickle-cell disease; SSS, superior sagittal sinus; TBI, traumatic brain injury; TFUS, transfontanellar ultrasonography; TIA, transient ischemic attack; TS, transverse sinus; yrs., years.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Florian, I.A.; Beni, L.; Moisoiu, V.; Timis, T.L.; Florian, I.S.; Balașa, A.; Berindan-Neagoe, I. ‘De Novo’ Brain AVMs—Hypotheses for Development and a Systematic Review of Reported Cases. Medicina 2021, 57, 201. https://doi.org/10.3390/medicina57030201

AMA Style

Florian IA, Beni L, Moisoiu V, Timis TL, Florian IS, Balașa A, Berindan-Neagoe I. ‘De Novo’ Brain AVMs—Hypotheses for Development and a Systematic Review of Reported Cases. Medicina. 2021; 57(3):201. https://doi.org/10.3390/medicina57030201

Chicago/Turabian Style

Florian, Ioan Alexandru, Lehel Beni, Vlad Moisoiu, Teodora Larisa Timis, Ioan Stefan Florian, Adrian Balașa, and Ioana Berindan-Neagoe. 2021. "‘De Novo’ Brain AVMs—Hypotheses for Development and a Systematic Review of Reported Cases" Medicina 57, no. 3: 201. https://doi.org/10.3390/medicina57030201

Article Metrics

Back to TopTop